Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 2/20 | 0.39 |
| ▸ | PAM | P19021 | 1/20 | 0.39 |
| ▸ | DHFR | P00374 | 1/20 | 0.39 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 4/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1065322 | 1.00 | MAOB (0.44) | MAOBKDM4EIDO1PAMDHFR | |
| SCHEMBL10748019 | 0.87 | MAOB (0.55) | MAOBKDM4EIDO1PAMPRMT1 | |
| SCHEMBL6665965 | 0.87 | MAOB (0.55) | MAOBKDM4EIDO1PAMPRMT1 | |
| SCHEMBL29285201 | 0.84 | KDM4E (0.45) | MAOBKDM4EIDO1PAMDHFR | |
| SCHEMBL29285202 | 0.84 | KDM4E (0.45) | MAOBKDM4EIDO1PAMDHFR | |
| SCHEMBL28981265 | 0.82 | EGFR (0.53) | MAOBKDM4EDHFRRAB9AALDH1A1 | |
| SCHEMBL28981267 | 0.82 | EGFR (0.53) | MAOBKDM4EDHFRRAB9AALDH1A1 | |
| SCHEMBL20651287 | 0.82 | NFE2L2 (0.53) | MAOBKDM4ERAB9AHTR2AALDH1A1 | |
| SCHEMBL693125 | 0.82 | MAOB (0.53) | MAOBKDM4EIDO1PRMT1RAB9A | |
| SCHEMBL11254209 | 0.78 | KMT2A (0.54) | MAOBKDM4EPAMRAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7868204-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2011-01-11 | — | — | US | disclosed |
| US-7838520-B2 | Inhibitors of histone deacetylase | METHYLGENE, INC. (CA) | 2010-11-23 | — | — | US | disclosed |
| US-7595343-B2 | Inhibitors of histone deacetylase | METHYLGENE, INC. (CA) | 2009-09-29 | — | — | US | disclosed |
| US-20060058298-A1 | Inhibitors of histone deacetylase | METHYLGENE, INC. | 2006-03-16 | — | — | US | disclosed |
| EP-1590340-A1 | INHIBITORS OF HISTONE DEACETYLASE | Methylgene, Inc. (CA) | 2005-11-02 | — | — | EP | disclosed |
| US-6897220-B2 | Inhibitors of histone deacetylase | METHYLGENE, INC. (CA) | 2005-05-24 | — | — | US | disclosed |
| WO-2004069823-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE, INC. (CA) | 2004-08-19 | — | — | WO | disclosed |
| US-20040142953-A1 | Inhibitors of histone deacetylase | METHYLGENE, INC. | 2004-07-22 | — | — | US | disclosed |
| US-20040106599-A1 | Inhibitors of histone deacetylase | 92229129 QUEBEC INC. (CA) | 2004-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106599-A1 | Inhibitors of histone deacetylase | HDAC1, HDAC5, HDAC3 | MAOB 2499/4885KDM4E 123/4885IDO1 1325/4885 |
| US-20060058298-A1 | Inhibitors of histone deacetylase | HDAC1, HDAC5, HDAC3 | MAOB 2499/4885KDM4E 123/4885IDO1 1325/4885 |
| US-20040142953-A1 | Inhibitors of histone deacetylase | HDAC1, HDAC5, HDAC3 | MAOB 2499/4885KDM4E 123/4885IDO1 1325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.